EPO and chronic kidney disease: In this regard, a recent cross-sectional study including 96 patients undergoing dialysis showed that increased serum levels of thrombosis-related biomarkers (e.g., plasminogen activator inhibitor-1 and L-type fatty acid binding protein) were associated with an increased risk of EPO hyporesponsiveness [30]; such mediators can be found both in patients with advanced CKD and in those exposed to SARS-CoV-2, two conditions characterized by increased thrombotic risk [31,32].